In MASLD patients with fibrosis stage 2–3, there was a higher prevalence of type 2 diabetes mellitus and hypertension, as well as higher serum levels of ALT, AST, and triglycerides, compared to MASLD patients with fibrosis stage 0–1. The gene discussed is GPT; the disease is diabetes mellitus.